nevirapine has been researched along with Liver Dysfunction in 19 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both chronic hepatitis C and nevirapine (NVP) use are risk factors for transaminase elevation under highly active antiretroviral therapy." | 7.72 | Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. ( González-Lahoz, J; González-Requena, D; Núñez, M; Soriano, V, 2003) |
| " Women appear to be at an especially high risk for lactic acidosis, nevirapine-associated rashes and hepatotoxicity, and fat redistribution after highly active antiretroviral therapy exposure." | 4.82 | Sex differences in antiretroviral therapy-associated intolerance and adverse events. ( Clark, R, 2005) |
| "Both chronic hepatitis C and nevirapine (NVP) use are risk factors for transaminase elevation under highly active antiretroviral therapy." | 3.72 | Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. ( González-Lahoz, J; González-Requena, D; Núñez, M; Soriano, V, 2003) |
| "immediate allergy and increased hepatotoxicity (regardless of chronic infection with hepatitis B or C virus and methadone use) for nevirapine." | 2.71 | Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. ( Calza, L; Chiodo, F; Manfredi, R, 2004) |
| " We characterized relationships between nevirapine-associated cutaneous and hepatic adverse events and genetic variants among HIV-infected adults." | 1.37 | Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. ( Cammett, AM; Distel, M; Guo, S; Haas, DW; Hall, D; Huang, Z; Jayadev, S; Mootsikapun, P; Podzamczer, D; Ruxrungtham, K; Storfer, S; Yuan, J, 2011) |
| "Liver diseases are common in patients with HIV due to viral hepatitis B and C co-infections, opportunistic infections or malignancies, antiretroviral drugs and drugs for opportunistic infections." | 1.35 | The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. ( Colebunders, R; Feld, J; Kambugu, A; Katabira, E; Katwere, M; Ocama, P; Opio, KC; Piloya, T; Ronald, A; Thomas, D, 2008) |
| "The stage of liver fibrosis was assessed by liver biopsy and/or elastography." | 1.33 | Severe liver disease associated with prolonged exposure to antiretroviral drugs. ( Babudieri, S; Barreiro, P; Garcia-Samaniego, J; González-Lahoz, J; Maida, I; Martín-Carbonero, L; Mura, MS; Núñez, M; Ríos, MJ; Rivas, P; Soriano, V; Sotgiu, G; Toro, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (94.74) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ocama, P | 1 |
| Katwere, M | 1 |
| Piloya, T | 1 |
| Feld, J | 1 |
| Opio, KC | 1 |
| Kambugu, A | 1 |
| Katabira, E | 1 |
| Thomas, D | 1 |
| Colebunders, R | 1 |
| Ronald, A | 1 |
| Yuan, J | 1 |
| Guo, S | 1 |
| Hall, D | 1 |
| Cammett, AM | 1 |
| Jayadev, S | 1 |
| Distel, M | 1 |
| Storfer, S | 2 |
| Huang, Z | 1 |
| Mootsikapun, P | 1 |
| Ruxrungtham, K | 2 |
| Podzamczer, D | 1 |
| Haas, DW | 3 |
| Núñez, M | 2 |
| González-Requena, D | 1 |
| González-Lahoz, J | 2 |
| Soriano, V | 3 |
| Pulido, F | 1 |
| Torralba, M | 1 |
| Law, WP | 1 |
| Dore, GJ | 1 |
| Duncombe, CJ | 1 |
| Mahanontharit, A | 1 |
| Boyd, MA | 1 |
| Lange, JM | 1 |
| Phanuphak, P | 1 |
| Cooper, DA | 1 |
| Ena, J | 1 |
| Amador, C | 1 |
| Benito, C | 1 |
| Fenoll, V | 1 |
| Pasquau, F | 1 |
| Dieterich, DT | 1 |
| Robinson, PA | 1 |
| Love, J | 1 |
| Stern, JO | 1 |
| Manfredi, R | 1 |
| Calza, L | 1 |
| Chiodo, F | 1 |
| Aranzabal, L | 1 |
| Casado, JL | 1 |
| Moya, J | 1 |
| Quereda, C | 1 |
| Diz, S | 1 |
| Moreno, A | 2 |
| Moreno, L | 1 |
| Antela, A | 1 |
| Perez-Elias, MJ | 1 |
| Dronda, F | 1 |
| Marín, A | 1 |
| Hernandez-Ranz, F | 1 |
| Moreno, S | 1 |
| De Requena, DG | 1 |
| Jiménez-Nácher, I | 1 |
| Clark, R | 1 |
| Maida, I | 1 |
| Ríos, MJ | 1 |
| Martín-Carbonero, L | 1 |
| Sotgiu, G | 1 |
| Toro, C | 1 |
| Rivas, P | 1 |
| Barreiro, P | 1 |
| Mura, MS | 1 |
| Babudieri, S | 1 |
| Garcia-Samaniego, J | 1 |
| Ritchie, MD | 1 |
| Motsinger, AA | 1 |
| Donahue, JP | 1 |
| Erdem, H | 1 |
| Raffanti, S | 1 |
| Rebeiro, P | 1 |
| George, AL | 1 |
| Kim, RB | 2 |
| Haines, JL | 1 |
| Sterling, TR | 1 |
| Bartlett, JA | 1 |
| Andersen, JW | 1 |
| Sanne, I | 1 |
| Wilkinson, GR | 1 |
| Hinkle, J | 1 |
| Rousseau, F | 1 |
| Ingram, CD | 1 |
| Shaw, A | 1 |
| Lederman, MM | 1 |
| Sandrine, PF | 1 |
| Sylvie, A | 1 |
| André, E | 1 |
| Abdoulaye, D | 1 |
| Bernard, L | 1 |
| André, C | 1 |
| Kumarasamy, N | 1 |
| Venkatesh, KK | 1 |
| Devaleenal, B | 1 |
| Palanivel, V | 1 |
| Cecelia, AJ | 1 |
| Muthu, S | 1 |
| Yepthomi, T | 1 |
| Mayer, KH | 1 |
| Flanigan, T | 1 |
| De Lazzari, E | 1 |
| León, A | 1 |
| Arnaiz, JA | 1 |
| Martinez, E | 1 |
| Knobel, H | 1 |
| Negredo, E | 1 |
| Clotet, B | 1 |
| Montaner, J | 1 |
| Asenjo, MA | 1 |
| Mallolas, J | 1 |
| Miró, JM | 1 |
| Gatell, JM | 1 |
| Sulkowski, MS | 1 |
| Thomas, DL | 1 |
| Mehta, SH | 1 |
| Chaisson, RE | 1 |
| Moore, RD | 1 |
| Imperiale, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Long-term Follow-up Study for HIV-infected Individuals Who Have Participated in HIV-NAT Study Protocols[NCT00411983] | 10,000 participants (Anticipated) | Observational | 2002-11-30 | Recruiting | |||
| Hepatic Safety of Currently Used Antiretroviral Regimens in HIV-infected Patients With Chronic Hepatitis B and/or Hepatitis C Under Real Life Conditions: The HEPAVIR HEPATIC SAFETY Cohort.[NCT01908660] | 192 participants (Actual) | Observational [Patient Registry] | 2007-01-31 | Completed | |||
| Multicenter, Pilot Study of Telbivudine (LdT) Anti-HBV Treatment Prior to the Initiation of Highly Active Antiretroviral Therapy Containing Lamivudine in Subjects Coinfected With HBV and HIV[NCT00051090] | 0 participants (Actual) | Interventional | Withdrawn | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for nevirapine and Liver Dysfunction
| Article | Year |
|---|---|
NNRTI hepatotoxicity: efavirenz versus nevirapine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Hepat | 2002 |
Sex differences in antiretroviral therapy-associated intolerance and adverse events.
Topics: Acidosis, Lactic; Anti-Retroviral Agents; Didanosine; Exanthema; Female; HIV Infections; Humans; Liv | 2005 |
Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Drug Therapy, | 2008 |
2 trials available for nevirapine and Liver Dysfunction
| Article | Year |
|---|---|
Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Diseases | 2004 |
Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical | 2007 |
14 other studies available for nevirapine and Liver Dysfunction
| Article | Year |
|---|---|
The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda.
Topics: Anti-HIV Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Comorbidity; Female; | 2008 |
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.
Topics: Adolescent; Adult; Asian People; Black People; CD4-Positive T-Lymphocytes; Female; Genetic Variation | 2011 |
Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
Topics: Alanine Transaminase; Anti-HIV Agents; Antibodies, Viral; Antiretroviral Therapy, Highly Active; Che | 2003 |
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclop | 2003 |
Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
Topics: Adult; Alanine Transaminase; Alcoholism; Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug I | 2003 |
Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.
Topics: Adult; Chemical and Drug Induced Liver Injury; Female; HIV Infections; Humans; Liver; Liver Diseases | 2004 |
Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and D | 2005 |
Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Chemical and Drug Induced | 2005 |
Severe liver disease associated with prolonged exposure to antiretroviral drugs.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Ascites; Budd-Chiari Syndrome; Case-C | 2006 |
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Case-Control Studies; | 2006 |
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.
Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Chemical and Drug Induc | 2006 |
Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect?
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur | 2007 |
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspart | 2002 |
Nevirapine-associated toxicity.
Topics: Anti-HIV Agents; Exanthema; HIV Infections; Humans; Liver Diseases; Nevirapine | 2002 |